A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2029

Conditions

Advanced Solid TumorMelanomaLung NeoplasmsHead and Neck Neoplasms

Interventions

DRUG

KSQ-001EX

Given by IV

DRUG

Interleukin-2

Given by IV

DRUG

Cyclophosphamide

Given by IV

DRUG

Fludarabine

Given by IV

Trial Locations (1)

MD Anderson Cancer Center, Houston